uniQure (QURE), CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. IBM
4. META
5. NAVN
6. DFTX
7. CNC
8. KFY
9. SPY
10. MU

Go back to uniQure (QURE), CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
CARLISLE COMPANIES, Inc. (NYSE: CSL) Delayed: 360.96 --0 (-0%)
Previous Close $360.96    52 Week High $114.49 
Open $360.96    52 Week Low $75.17 
Day High $360.96    P/E 99.99 
Day Low $360.96    EPS $3.61 
Volume 2       

(AMEX: CSLLY) Delayed: 19.88 --0 (-0%)
Previous Close $19.88    52 Week High $45.60 
Open $19.88    52 Week Low $33.39 
Day High $19.88    P/E N/A 
Day Low $19.88    EPS $0.00 
Volume 1,890       

UNIQURE (NASDAQ: QURE) Delayed: 44.39 --0 (-0%)
Previous Close $44.39    52 Week High $22.79 
Open $44.39    52 Week Low $6.63 
Day High $44.39    P/E N/A 
Day Low $44.39    EPS $0.00 
Volume 13,344